cognivue clarity®
Computerized Cognitive Assessment Device

LEADING THE WAY IN EARLY DETECTION OF COGNITIVE IMPAIRMENT

The increased demand for cognitive assessment and diagnosis for earlier detection of Mild Cognitive Impairment (MCI) will require a standardized and efficient approach to testing. Cognivue Clarity® provides a computerized cognitive assessment that is customized to each patient's ability—providing a sensitive, standardized, and sophisticated approach to testing.

COGNIVUE® OVERVIEW: ADVANCING COGNITIVE HEALTH

Our mission is to provide cognitive assessment tools to a broad range of healthcare providers for the early detection of cognitive impairment. Early detection allows patients to address modifiable risk factors sooner, potentially changing the course of cognitive decline. It also allows healthcare providers to develop a plan with the patient and caregiver, so the patient can live their best life during their journey.



Cognivue's proprietary technology removes the bias that is commonly associated with traditional cognitive assessment tools. The technology is based on adaptive psychophysics which customizes the cognitive assessment to an individual's motor and visual capabilities. This calibration creates a test and results that are unique to each patient, providing an in-depth, comprehensive, and objective test result.

2005
- Cerebral Assessment Systems (CAS) Founded
- NIH funded research led to 1st generation technology

2015
- FDA 510K De Novo Clearance received on Cognivue device

2018
- CAS acquired by Tom Golisano
- Company name changed to Cognivue
- Launch of Cognivue Advanced®

2020
- Launch of Cognivue Thrive® and Cognivue Clarity® Devices
- Lower profile and portable devices

2022
- Completed 1,500 patient FOCUS study
- Enhanced normative ranges sets a new gold standard for sensitivity and patient profiling

www.highlyreimbursable.com

cognivue®

cognivue clarity®

Computerized Cognitive Assessment Device



WHAT IS COGNIVUE CLARITY®?

Cognivue Clarity is an FDA-cleared, self-administered, digital cognitive assessment device that standardizes the patient's experience and removes potential in administration and scoring bias that can occur with traditional testing methods.

Our proprietary technology collects over 130,000 data points per patient test and is adaptive to each patient. Testing exercises assess the domains of Memory, Executive Function/Attention, Discrimination, and Visuospatial, as well as two speed performance parameters of reaction time and speed processing.

Self-Administered
Objective, self-administered test assessment that removes the potential for administration and scoring bias

10 Minutes
10-minute assessment based on FDA-cleared technology

Comprehensive Report
Automated scoring generates an easy-to-understand report

Dynamic Testing
Unique, customized patient testing experience

Schedule your Cognivue Clarity DEMO today!

Contact Moe Woodard (404-309-5200), or e-mail highlyreimbursable@gmail.com.

Scan or visit www.highlyreimbursable.com

cognivue®